We rank companies based on fund manager, research analyst and news sentiment
CBUS stock icon

Cibus
CBUS

$15.61
4%
 

About: Cibus Inc is a biotechnology company. The company develops and commercializes a proprietary gene-editing technology, Rapid Trait Development System that integrates crop specific cell biology platforms with a series of gene editing technologies. The company's primary business is the development of plant traits that help address specific productivity or yield challenges in farming such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate.

Employees: 183

0
Funds holding %
of 6,474 funds
Analysts bullish %
0
News positive %
of 5 articles

Fund manager confidence

Based on 2023 Q4 SEC filings by fund managers ($100M+ AUM)

333% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 3

43% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 7

29% more capital invested

Capital invested by funds: $86.2M [Q3] → $111M (+$24.7M) [Q4]

10% more funds holding

Funds holding: 30 [Q3] → 33 (+3) [Q4]

1.65% more ownership

Funds ownership: 28.43% [Q3] → 30.08% (+1.65%) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 2 [Q3] → 2 (+0) [Q4]

Research analyst outlook

1 Wall Street Analyst provided 1 year price forecasts over the past 6 months

Low target
$25
60%
upside
Avg. target
$25
60%
upside
High target
$25
60%
upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Amit Dayal
60%upside
$25
Buy
Maintained
22 Mar 2024

Financial journalist opinion

Based on 5 articles about CBUS published over the past 30 days